Shares of Zogenix (ZGNX) fell 45% after a Food and Drug Administration advisory committee reviewing its extended-release painkiller Zohydro voted 11-2 against the drug. Much of the resistance from the committee focused on potential abuse of the drug, and Zohydro in its current form is not crush-resistant. In this video, Motley Fool health care bureau chief Brenton Flynn tells us why this is such a devastating blow for the company, and what, if anything, in Zogenix's pipeline may save it.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.